|
|
|
|
| 灯盏花制剂治疗急性脑梗死 |
|
|
|
|
|
| Dengzhanhua preparations for acute cerebral infarction |
|
|
|
|
|
| Cao W., Liu W., Wu T., Zhong D., Liu G. 2009/5/29 18:39:20 |
|
|
【发表评论】
|
|
|
|
|
打印|
推荐给好友
|
|
|
Cochrane Database of Systematic Reviews, 2008, Volume 0, Issue 4
|
|
|
|
|
|
|
| Background: Dengzhanhua preparations are widely used in China. Many controlled trials have been undertaken to investigate the efficacy of dengzhanhua preparations in the treatment of acute cerebral infarction. Objectives: To assess whether dengzhanhua preparations are effective and safe at improving outcomes in patients with acute cerebral infarction. Search strategy: We searched the Cochrane Stroke Group Trials Register (last searched October 2007), the Chinese Stroke Trials Register (last searched June 2006), the trials register of the Cochrane Complementary Medicine Field (last searched June 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2 2006), MEDLINE (1966 to June 2006), EMBASE (1980 to June 2006), AMED (the Allied and Complementary Medicine Database, 1985 to June 2006), the China Biological Medicine Database (CBM-disc, 1979 to June 2006), and Chinese Knowledge Infrastructure (CNKI,1994 to October 2007). We also searched the reference lists of relevant articles. Selection criteria: Randomised and quasi-randomised controlled clinical trials of dengzhanhua preparations regardless of duration, dosage and route of administration in patients with confirmed acute cerebral infarction. Data collection and analysis: Two review authors independently applied the inclusion criteria, assessed trial quality, and extracted the data. Main results: We included nine trials, all conducted in China, involving 723 participants. Themethod of randomisation and concealment was poorly described. The included trials compared dengzhanhua injection plus routine therapy with routine therapy alone. Patients were enrolled up to one week after the onset of stroke. No trials reported data on the pre-specified primary or secondary outcomes. In a post-hoc comparison of dengzhanhua injection plus routine therapy versus routine therapy alone, dengzhanhua injection showed a statistically significant benefit on the outcome 'marked neurologic improvement' (relative risk 1.53; 95% confidence interval 1.36 to 1.72). No serious adverse effects were reported. Authors' conclusions: Due to the generally low methodological quality and small sample size of the included trials in this systematic review, we could not draw a firm conclusion. Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
|
|
|
|
|
|
| Correspondence Address: Liu, G.; Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China; email: ceuliu@hotmail.com |
|
|
|
|
|
|
|
|
|
|
|
请登录后发表评论，点击此处登录。
|
|
|
 疾病资源中心
王燕燕 王曙
上海交通大学附属瑞金医院内分泌科
患者，女，69岁。2009年1月无明显诱因下出现乏力，当时程度较轻，未予以重视。2009年3月患者乏力症状加重，尿色逐渐加深，大便习惯改变，颜色变淡。4月18日入我院感染科治疗，诉轻度头晕、心慌，体重减轻10kg。无肝区疼痛，无发热，无腹痛、腹泻、腹胀、里急后重，无恶性、呕吐等。入院半月前于外院就诊，查肝功能：ALT 601IU/L，AST 785IU/L，TBIL 97.7umol/L，白蛋白 41g/L，甲状腺功能：游离T3 30.6pmol/L，游离T4 51.9pmol/L，心电图示快速房颤。
医学数据库
|
